Gottlieb: FDA, CMS Eye New Non-Volume-Based Pay Model For Antibiotics

By David Roza / June 14, 2018 at 8:02 PM

FDA Commissioner Scott Gottlieb said he is discussing with CMS the possibility of a new license-based reimbursement model for antibiotics that would spare drug makers some of the disincentives that usually come with antibiotic development, such as the low volume of sales that occur when providers try to use antibiotics sparingly.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.